MARKET

SCYX

SCYX

SCYNEXIS
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.125
-0.035
-3.02%
After Hours: 1.120 -0.005 -0.44% 17:57 11/15 EST
OPEN
1.150
PREV CLOSE
1.160
HIGH
1.160
LOW
1.110
VOLUME
191.17K
TURNOVER
--
52 WEEK HIGH
1.900
52 WEEK LOW
0.3500
MARKET CAP
64.53M
P/E (TTM)
-1.9589
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of SCYX and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

SCYX News

  • SCYNEXIS Commends the CDC for the Recognition of Candida auris as a New "Urgent Threat" in its Updated Report on Antibiotic Resistance Threats in the United States
  • PR Newswire.2d ago
  • Scynexis (SCYX) Reports Q3 Loss, Lags Revenue Estimates
  • Zacks.4d ago
  • SCYNEXIS Q3 EPS $(0.14) Down From $0.01 YoY
  • Benzinga.4d ago
  • SCYNEXIS Reports Third Quarter 2019 Financial Results and Provides Company Update
  • PR Newswire.4d ago

More

Industry

Pharmaceuticals
+1.37%
Pharmaceuticals & Medical Research
+1.34%

Hot Stocks

Name
Price
%Change

About SCYX

SCYNEXIS, Inc. is engaged in the discovery, development and commercialization of anti-infectives. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species, including drug-resistant strains. The Company also conducts additional in vitro and in vivo studies to further characterize the spectrum of activity of SCY-078. The Company has completed multiple Phase I studies with the oral formulation of SCY-078 and is conducting its first Phase I study with the IV formulation of SCY-078. The Company has also developed a platform for cyclophilin inhibitors, which has two clinical stage compounds, such as SCY-635 and SCY-641.
More

Webull offers SCYNEXIS Inc (SCYX) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.